Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer

Immune-related adverse events (IRAEs) are a common yet problematic phenomenon in patients who are treated with immune checkpoint inhibitors (ICIs). Current research efforts have explored the exact pathophysiology of IRAEs in the clinical setting. However, a rare subset of IRAEs that is less highligh...

Descripción completa

Detalles Bibliográficos
Autores principales: Baroz, Angel R, Mambetsariev, Isa, Fricke, Jeremy, Pharaon, Rebecca, Tan, TingTing, Kidambi, Trilokesh, Sandhu, Karamjeet S, Koczywas, Marianna, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349225/
https://www.ncbi.nlm.nih.gov/pubmed/34377604
http://dx.doi.org/10.7759/cureus.16266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349225/
https://www.ncbi.nlm.nih.gov/pubmed/34377604
http://dx.doi.org/10.7759/cureus.16266

Ejemplares similares